Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randolph Marks

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 3, 2011
Worse disease-free survival in never-smokers with ALK+ lung adenocarcinomaPing Yang, Kimary Kulig, Jennifer M Boland, et al.
Cancer Treatment and Research Communications|August 2, 2023
Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief reportAakash Desai, Sagar Rakshit, Radhika Bansal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597Daniel D Karp, Sandra J Lee, Steven M Keller, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 3, 2011
Worse disease-free survival in never-smokers with ALK+ lung adenocarcinomaPing Yang, Kimary Kulig, Jennifer M Boland, et al.
Cancer Treatment and Research Communications|August 2, 2023
Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief reportAakash Desai, Sagar Rakshit, Radhika Bansal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597Daniel D Karp, Sandra J Lee, Steven M Keller, et al.
Pageof 2